Share chart X4 Pharmaceuticals, Inc.
Extended chart
Simple chart
About X4 Pharmaceuticals, Inc.
X4 Pharmaceuticals, Inc., клиническая биофармацевтическая компания поздней стадии, занимается исследованиями, разработкой и коммерциализацией новых терапевтических средств для лечения редких заболеваний. more details| IPO date | 2017-11-16 |
|---|---|
| ISIN | US98420X1037 |
| Industry | Biotechnology |
| Sector | Health Care |
| Валюта | usd |
| Валюта отчета | usd |
| Сайт | https://www.x4pharma.com |
| Цена ао | 0.2694 |
| Change price per day: | 0% (0.2694) |
|---|---|
| Change price per week: | -11.38% (0.304) |
| Change price per month: | -38.21% (0.436) |
| Change price per 3 month: | -66.58% (0.806) |
| Change price per half year: | -58.87% (0.655) |
| Change price per year: | -80.62% (1.39) |
| Change price per 3 year: | -86.66% (2.02) |
| Change price per 5 year: | -97.47% (10.63) |
| Change price per year to date: | -63.3% (0.734) |
|
|
Underestimation
|
Efficiency
|
|||||||||||||||||||||||||||||||||||||
Dividends
|
Debt
|
Growth impulse
|
|||||||||||||||||||||||||||||||||||||
| Institutions | Volume | Share, % |
|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 15960588 | 9.54 |
| NEA Management Company, LLC | 14986793 | 8.96 |
| Blackrock Inc. | 8156841 | 4.88 |
| Vanguard Group Inc | 7824717 | 4.68 |
| Polar Capital Holdings PLC | 7500000 | 4.48 |
| Orbimed Advisors LLC. | 7133515 | 4.26 |
| Tri Locum Partners, LP | 6247500 | 3.73 |
| Stonepine Capital Management, LLC | 5273685 | 3.15 |
| Adage Capital Partners GP L.L.C. | 4276315 | 2.56 |
| Millennium Management LLC | 3615964 | 2.16 |
| ETF | Share, % | Profitability for 1 year, % | Dividends, % |
|---|---|---|---|
| iShares Micro-Cap ETF | 0.03006 | 17.09 | 1.54048 |
| Vanguard Russell 2000 Growth ETF | 0.01 | 23.05 | 0.60264 |
iShares Russell 2000 Growth ETF
|
0.00943 | 38.04 | 0.6026 |
ProShares UltraPro Russell2000
|
0.00257 | 89.82 | 1.47873 |
| ProShares Hedge Replication ETF | 0.00072 | 5.92 | 1.47892 |
| iShares Russell 3000 ETF | 0.00026 | 24.83 | 1.43482 |
| Vanguard Russell 2000 ETF | 0 | 17.16 | 1.48801 |
| Vanguard Russell 3000 ETF | 0 | 31.87 | 1.43817 |
| 0.01 | 30.97 | 1.26 |
| Head | Job title | Payment | Year of birth |
|---|---|---|---|
| Dr. Paula Ragan Ph.D. | CEO, President & Director | 963.58k | 1970 (55 years) |
| Mr. Adam S. Mostafa | CFO, Treasurer & Corporate Secretary | 699.18k | 1980 (45 years) |
| Dr. Mary DiBiase Ph.D. | Chief Operating Officer | 661.59k | 1961 (64 years) |
| Dr. Richard Peters M.D., Ph.D. | Founder | N/A | 1963 (62 years) |
| Dr. Renato T. Skerlj Ph.D. | Founder | N/A | |
| Dr. Keith T. Flaherty M.D. | Founder & Member of Corporate Advisory Board | N/A | 1971 (54 years) |
| Dr. Arthur Taveras Ph.D. | Chief Scientific Officer | N/A | 1964 (61 year) |
| Dr. Robert David Arbeit | Senior Vice President of Clinical Development and Translational Research | N/A | 1948 (77 years) |
| Mr. Mark Baldry M.B.A. | Chief Commercial Officer | N/A | 1964 (61 year) |
| Dr. Christophe Arbet-Engels M.B.A., M.D., Ph.D. | Chief Medical Officer | 1962 (63 years) |
Address: United States, Boston. MA, 61 North Beacon Street - open in Google maps, open in Yandex maps
Website: https://www.x4pharma.com
Website: https://www.x4pharma.com
